A Phase IIIB study to evaluate the use of capivasertib in combination with fulvestrant in patients with advanced breast cancer who have relapsed/progressed on ET and CDK4/6 inhibitor reflecting Real World Clinical Practice in Spain

Trial Identifier: D3612L00005
Sponsor: AstraZeneca
Collaborator:
APICES Soluciones S.L.
SOLTI
Start Date: January 2025
Primary Completion Date: December 2027
Study Completion Date: December 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
ES Alicante, ES, 03010
ES Barcelona, ES, 08035
ES Barcelona, ES, 08036
ES Barcelona, ES, 08003
ES Bilbao (Vizcaya), ES, 48013
ES Cáceres, ES, 10003
ES Córdoba, ES, 14004
ES Donostia, ES, 20014
ES El Palmar, ES, 30120
ES Girona, ES, 17007
ES Madrid, ES, 28041
ES Oviedo, ES, 33011
ES Palma deMallorca, ES, 07010
ES Salamanca, ES, 37007
ES Santander, ES, 39008
ES Sevilla, ES, 41073
ES Valencia, ES, 46026
ES Zaragoza, ES, 50009